Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival

Breast Cancer Research and Treatment

Volumn 100, Issue 2, 2006, Pages 161-167

  Kostadima, L ^a   Pentheroudakis, G ^a   Fountzilas, G ^a   Dimopoulos, M ^a   Pectasides, D ^a   Gogas, H ^a   Christodoulou, C ^a   Samantas, E ^a   Bafaloukos, D ^a   Arapantoni, P ^a   Kalofonos, H ^a   Papakostas, P ^a   Economopoulos, T ^a   Bamias, A ^a   Pavlidis, N ^a   Stropp, U ^b   Wirtz, R ^b   Hennig, G ^b  

^a Hellenic Cooperative Oncology Group   (Greece)

^b BAYER AG   (Germany)

Author keywords

Early breast cancer; Glycodelin; Survivin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PLACENTA PROTEIN 14; PROTEIN P53; SURVIVIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BIOPSY; BREAST CANCER; CANCER STAGING; CELL SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GENES, ERBB-2; GLYCOPROTEINS; HUMANS; LYMPHATIC METASTASIS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PREGNANCY PROTEINS; RNA, MESSENGER;

EID: 33750308057     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9240-x     Document Type: Article

References (25)

1. Seppala M, Bohn H, Tatarinov Y (1998) Glycodelins. Tumour Biol 19:213-220
2. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54
3. Fountzilas G, Skarlos D, Dafni U, et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer. Ann Oncol 16:1762-1771
4. Kamarainen M, Halttunen M, Koistinen R, von Bogulsawsky K, von Smitten K, et al (1999) Expression of glycodelin in human breast and breast cancer. Int J Cancer 83:738-742
5. Dell A, Morris HR, Easton RL, Panico M, Patankar M, et al (1995) Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J Biol Chem 270:24116-24126
6. Jeschke U, Wang X, Briese V, Friese K, Stahn R (2003) Glycodelin and amniotic fluid transferrin as inhibitors of E-selectin-mediated cell adhesion. Histochem Cell Biol 119:345-354
7. Song M, Ramaswamy S, Ramachandran S, Flowers LC, Horowitz IR, et al (2001) Angiogenic role for glycodelin in tumorigenesis. Proc Natl Acad Sci USA 98:9265-9270
8. Horowitz IR, Cho C, Song M, Flowers LC, Santanam N, et al (2001) Increased glycodelin levels in gynecological malignancies. Int J Gynecol Cancer 11:173-179
9. Vaisse C, Atger M, Potier B, Milgrom E (1990) Human placental protein 14 gene: sequence and characterization of a short duplication. DNA Cell Biol 9:401-413
10. Jeschke U, Mylonas I, Kunert-Keil C, Dazert E, Shabani N, et al (2005) Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence. Oncol Rep 13:413-419
11. Kamarainen M, Seppala M, Virtanen I, Andersson LC (1997) Expression of glycodelin in MCF7 breast cancer cells induces differentiation into organized acinar epithelium. Lab Invest 77:565-573
12. Garde J, Bell SC, Eperon IC (1991) Multiple forms of mRNA encoding human pregnancy-associated endometrial a2-globulin, a β-lactoglobulin homologue. Proc Nat Acad Sci 88:2456-2460
13. Ambrosini G, Adida C, Altieri DC (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
14. Reed JC, Bischoff JR (2000) BIRinging chromosomes through cell division-and survivin' the experience. Cell 102:545-548
15. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, et al (1999) Analysis of human transcriptomes. Nat Genet 23:387-388
16. Span PN, Sweep FC, Wiegerinck ETG, Tjan-Heijnen V, Manders P, et al (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986-1993
17. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol Jan 10:DOI 10.1093/annonc/mdj121
18. Blanc-Brude OP, Mesri M, Wall NR, et al (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692
19. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, et al (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-19
20. Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, et al (2005) Comparison of extracellular matrix and apoptotic markers between lesions and carcinomas in human breast. Int J Oncol 27:1005-1011
21. Tsuji N, Fuuse K, Asanuma K, et al (2004) Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer. Breast Cancer Res Treat 87:23-31
22. Mirza A, McGuirk M, Hockenberry TN, et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622
23. Tanaka K, Iwamoto S, Gon G, et al (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134
24. O'Driscoll L, Linehan R, Kennedy S, et al (2003) Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 201:225-236
25. Chu JS, Shew JY, Huang CS (2004) Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 103:925-931